Genesystem Co (XKRX:363250) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Genesystem Co Debt-to-Equity?

Genesystem Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0.0 Mil. Genesystem Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0.0 Mil. Genesystem Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩25,306.1 Mil. Genesystem Co's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Genesystem Co's Debt-to-Equity or its related term are showing as below:

XKRX:363250' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.11 Max: 0.32
Current: 0.18

During the past 5 years, the highest Debt-to-Equity Ratio of Genesystem Co was 0.32. The lowest was 0.09. And the median was 0.11.

XKRX:363250's Debt-to-Equity is ranked better than
58.55% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs XKRX:363250: 0.18

Genesystem Co Debt-to-Equity Historical Data

The historical data trend for Genesystem Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genesystem Co Debt-to-Equity Chart

Genesystem Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.05

0.32

0.09

0.12

0.16

Genesystem Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial											0.12	0.13	0.14	0.16	-

Competitive Comparison of Genesystem Co's Debt-to-Equity

For the Diagnostics & Research subindustry, Genesystem Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genesystem Co's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genesystem Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Genesystem Co's Debt-to-Equity falls into.

Genesystem Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Genesystem Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1380.502	+	3107.177)	/	27456.224
	=	0.16

Genesystem Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	25306.143
	=	0.00

Genesystem Co (XKRX:363250) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Genesystem Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Genesystem Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Genesystem Co (XKRX:363250) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genesystem Co Ltd (XKRX:363250) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

200-9, Techno 2-ro, Yuseong-gu, Daejeon, KOR, 34028

Website

http://www.genesystem.co.kr

Genesystem Co Ltd is a biotech engineering company specializing in molecular testing solutions that target on-site testing needs. It develops and markets state-of-the-art PCR platforms as well as related reagents and biochip products designed to enhance the health of human societies and improve the quality of human life.

Genesystem Co (XKRX:363250) Headlines

No Headlines